Vascodagama Online Journal

Respiratory syncytial virus (RSV) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies – Gilead Sciences

 Breaking News
  • No posts were found

Respiratory syncytial virus (RSV) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies – Gilead Sciences

June 08
23:13 2022
Respiratory syncytial virus (RSV) Market Size and Share Analysis, Growth Opportunities, Current Treatment Practices, Emerging Therapies, Epidemiology Forecast | Key Companies - Gilead Sciences
DelveInsight’s “Respiratory syncytial virus (RSV) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory syncytial virus (RSV), historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Respiratory syncytial virus (RSV) Market Insights, Epidemiology, and Market Forecast-2032”. 

 

DelveInsight’s “Respiratory syncytial virus (RSV) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory syncytial virus (RSV), historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the Respiratory syncytial virus (RSV) Market Report:

  • RSV is a respiratory virus that infects the lungs and breathing passages. Healthy people typically experience mild, cold-like symptoms and recover in a week or two 
  • The market size of Respiratory syncytial virus is estimated to grow at a significant CAGR  which will drive more competitors in the market 
  • Malosh et al. (2017) studied a cohort of hospitalized patients, wherein RSV was detected in 7% of hospitalized individuals 
  • As per a study conducted by Htar et al. (2020), in a cohort of patients suffering from acute respiratory tract infection (ARI), RSV accounted for 1–10% in adults and 2–14% in patients with chronic diseases or transplantation 
  •  

Request a sample for the Report: https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market

 

Key benefits of the report:

  1. Respiratory syncytial virus (RSV) market report covers a descriptive overview and comprehensive insight of the Respiratory syncytial virus (RSV) Epidemiology and Respiratory syncytial virus (RSV)  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Respiratory syncytial virus (RSV) market report provides insights on the current and emerging therapies.
  3. The respiratory syncytial virus (RSV) market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Respiratory syncytial virus (RSV) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Respiratory syncytial virus (RSV) market. 
  5.  

Got queries? Click here to know more about the Respiratory syncytial virus (RSV) Market Landscape 

 

Respiratory syncytial virus (RSV) Overview: 

Respiratory syncytial virus (RSV) is a highly contagious virus that affects the respiratory system. It is classified as a member of the genus Pneumovirus in the family Paramyxoviridae. Virus particles are enveloped and pleomorphic, occurring as irregular spherical particles that are 100–350 nm in diameter and as long filamentous fibers that are 60–200 nm in diameter and 10 mm in length.

The virion consists of eight structural proteins. Three proteins are associated with the nucleocapsid and include nucleoprotein (N), phosphoprotein (P), and polymerase or large protein (L). The other five viral proteins are contained within the virus envelope and include nonglycosylated matrix protein (M), M2, fusion protein (F), glycoprotein (G), and short hydrophobic protein (SH). RSV lacks hemagglutinin and neuraminidase activity. The viral genome consists of a linear, single-stranded, negative-sense, nonsegmented RNA (~15.2 kb). 

 

Respiratory syncytial virus (RSV) Symptoms: 

The Symptoms of Respiratory syncytial virus include –

Runny Nose

Sneezing 

Body Fatigue 

High Fever

Weakness 

 

Respiratory syncytial virus (RSV) Market  

The dynamics of the Respiratory syncytial virus (RSV) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as EDP-938, PC786,  and others during the forecasted period 2019-2032.

 

Learn more by requesting for sample @Respiratory syncytial virus (RSV) Market Landscape  

 

Respiratory syncytial virus (RSV) Pipeline Therapies: 

  • EDP-938
  • MEDI8897
  • PC786
  • ALN-RSV01
  • GS-5806 

 

Respiratory syncytial virus (RSV) Pipeline Key Companies: 

  • Gilead Sciences
  • AstraZeneca
  • Alnylam Pharmaceuticals
  • Janssen Research & Development

 

Table of Contents 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Respiratory syncytial virus (RSV) Patient Share (%) Overview at a Glance

5. Respiratory syncytial virus (RSV) Market Overview at a Glance

6. Respiratory syncytial virus (RSV) Disease Background and Overview

7. Respiratory syncytial virus (RSV) Epidemiology and Patient Population

8. Country-Specific Patient Population of Respiratory syncytial virus (RSV) 

9. Respiratory syncytial virus (RSV) Current Treatment and Medical Practices

10. Unmet Needs

11. Respiratory syncytial virus (RSV) Emerging Therapies

12. Respiratory syncytial virus (RSV) Market Outlook

13. Country-Wise Respiratory syncytial virus (RSV) Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Respiratory syncytial virus (RSV) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com